Phase I study of hepatic arterial infusion chemotherapy with gemcitabine and 5FU for postoperative liver metastases from pancreatic cancer.

Phase I study of hepatic arterial infusion chemotherapy with gemcitabine and 5FU for postoperative liver metastases from pancreatic cancer. - HAI chemotherapy with GEM+5FU

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011059

Enrollment

Registered

2013-07-01

Start date

2010-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative liver metastases from pancreatic cancer

Interventions

chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Postoperative liver metastases without another recurrent plase.

Exclusion criteria

Exclusion criteria: Another metastases or not R0 resection case.

Design outcomes

Primary

Measure	Time frame
adverse events	—

Countries

Japan

Contacts

Public ContactHidehiro Tajima

Kanazawa University Hospital Hepato-Biliary-Pancreatic Surgery

hidetaji@staff.kanazawa-u.ac.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026